CERVICAL CANCER SCREENING PROGRAMME

Reporting year for qualitative data:	2016
Source of qualitative data:	Other (EU Report 2017)

Organization of screening
An individual/team/institution responsible to coordinate the programme:	Yes
Dedicated budget for screening programme:	Yes
Documented cancer screening policy:	Yes
Nature of documentation of the policy:	Law
Year programme was initiated:	2006
Programme introduction was preceded by a pilot:	-
Screening tests provided free of charge:	Yes
Diagnostic tests provided free of charge:	-
Treatment services provided free of charge:	-
Information system and data collection
System that collects data:	Individual & Aggregated
• Identification of eligible population:	-
• Screening participation:	-
• Screening test results:	-
• Further assessment:	-
• Final pathology diagnosis:	-
• Cancer staging:	-
• Treatment:	-
The information system exists at national or sub-national level:	Individual: Unknown Aggregated: Unknown
The information system collects data outside the programme (opportunistic screening/private sector):	-
Cancer screening data is linked with population-based cancer registry (PBCR):	No
Screening protocol
A screening protocol or guideline:	-
Year of published/updated protocol:	-
Target age (min-max) and screening interval [months] for each test:	Cytology (25-29 years / [36 months]) (30-59 years / [36 months])
Triaging test used:	None
Self-collection HPV recommended:	-
"Screen and treat" included in the protocol:	-
Treatment modality for "screen and treat":	-
Invitations for screening and further assessment
Initiatives to create population awareness by the Health Ministry/Health Authority:	-
Invitations to eligible population:	Yes
Source of the eligible individuals identified:
Method of invitation:	Letter
Screening kit included with the invitation:	No
Screen positive individuals actively contacted for further assessment:	Yes
Individuals with a precancer or cancer diagnosis actively contacted:	-
Quality Assurance (QA) of screening activities
Documented standard operating procedure/policy for QA:	-
An individual/team/institution responsible for QA:	Yes
Accreditation of lab services:	-
Accreditation of pathology services:	-
Documented performance indicators:	-
Reference standards for performance indicators:	-
Evaluation reports published in the last five years:	Yes
Performance indicators
Reporting year for quantitative data:	2016
Source of quantitative data:	Report (EU Report 2017)
Age range and regional limitation if applicable:	All ages
Invitation coverage (%):
Participation rate (%):	18.2
Examination coverage (%):
Completeness of data related to screening test results (%):	100
Completeness of data related to further assessment results (%):	37.7
Further assessment (Colposcopy referral) rate (%):	1.2 (all ages)
Further assessment participation rate (%):	39.0 (all ages)
Detection rate for CIN2+ (x 1000):	1.04 (all ages)
Detection rate for CIN3+ (x 1000):	0.61 (all ages)
Detection rate for invasive cancer (x 1000):
Positive Predictive Value of abnormal screening test to detect CIN2+ (x 1000):	23.2 (all ages)
Positive Predictive Value for CIN3+ (x 1000):	13.5 (all ages)
Positive Predictive Value for invasive cancer (x 1000):
More quantitative data (2013/Cytology)

Check also the following factsheets: Poland, Breast, Colorectal